Amgen Inc. $AMGN Shares Sold by Baird Financial Group Inc.

Baird Financial Group Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 284,528 shares of the medical research company’s stock after selling 24,670 shares during the period. Baird Financial Group Inc.’s holdings in Amgen were worth $79,443,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Westwood Holdings Group Inc. increased its position in Amgen by 30.3% during the 1st quarter. Westwood Holdings Group Inc. now owns 15,606 shares of the medical research company’s stock worth $4,862,000 after purchasing an additional 3,631 shares in the last quarter. Commonwealth Financial Services LLC raised its holdings in Amgen by 6.2% in the first quarter. Commonwealth Financial Services LLC now owns 1,975 shares of the medical research company’s stock valued at $615,000 after buying an additional 116 shares during the period. Chicago Partners Investment Group LLC raised its holdings in Amgen by 21.1% in the first quarter. Chicago Partners Investment Group LLC now owns 5,839 shares of the medical research company’s stock valued at $1,819,000 after buying an additional 1,019 shares during the period. Finally, Deutsche Bank AG lifted its position in Amgen by 1.6% during the first quarter. Deutsche Bank AG now owns 3,266,009 shares of the medical research company’s stock valued at $1,017,525,000 after buying an additional 52,734 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 1.5%

Shares of AMGN opened at $340.16 on Friday. Amgen Inc. has a one year low of $253.30 and a one year high of $346.38. The stock has a 50-day moving average price of $312.27 and a 200 day moving average price of $296.72. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The company has a market capitalization of $183.17 billion, a P/E ratio of 26.29, a P/E/G ratio of 3.12 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.Amgen’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the company posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Friday, November 21st. Amgen’s dividend payout ratio is 73.57%.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 in the last ninety days. Corporate insiders own 0.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Daiwa Capital Markets increased their price objective on shares of Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. DZ Bank upped their price target on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Wells Fargo & Company set a $400.00 price target on Amgen in a report on Tuesday, November 25th. Weiss Ratings raised Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Finally, HSBC boosted their price objective on Amgen from $343.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $335.65.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.